New York, USA, April 17, 2023 (GLOBE NEWSWIRE) -- DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline Landscape
Crohn’s disease’s prevalence has been rising over the past few years, prompting the growing demand for treatment options. The increasing prevalence of Crohn’s disease and the growing research and development activities to develop novel therapies to treat Crohn’s disease to drive the market. The companies developing the potential therapies in the last stage of development include Janssen, RedHill Biopharma, Hoffmann-La Roche, Gilead Sciences, and several others.
DelveInsight’s 'Crohn's Disease Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline Crohn's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Crohn's disease pipeline domain.
Key Takeaways from the Crohn's Disease Pipeline Report
- DelveInsight’s Crohn's disease pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for Crohn's disease treatment.
- Key Crohn's disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Celularity, Cerecor, GlaxoSmithKline, KangStem Biotech, Immunic, Alpha Cancer Technologies, Koutif Therapeutics, Tract Therapeutics, Trio medicines, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, JHL Biotech, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, AbbVie, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Engitix, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Assembly Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo, and others are evaluating new Crohn's disease drugs to improve the treatment landscape.
- Promising Crohn's disease pipeline therapies such as Guselkumab, ABP-654, RHB-104, Etrolizumab, PRA-023, AGMB-129, Filgotinib, Mirikizumab, Ozanimod, Brazikumab, Remestemcel-L, Rifaximin, Foralumab, ABX-464, Etrasimod, CYTO-201, Masitinib, HAV anti-MAP vaccine, Alequel, Cannabidiol, SHR0302, QBECO-SSI, PRV-6527, PF-06651600, MT-1303, TAK-018, SGX203, IMU 838, Alicaforsen, Bacteroides thetaiotaomicron, BT-11, JNJ-64304500, E6011, BMS-986165, Spesolimab, Aldesleukin, CBP-307, TD-1473, JKB-122, PDA-001, MDGN-002, GSK1070806, Furestem-CD, IMU-856, ACT-101, KT-1002, TregCel, TR8, CCX507, NP-178, NeuLara, JHL1255, Anti-inflammatory drug LIS, Brilacidin, Research programme: anti-fibrotic therapeutics Faecalibacterium Prausnitzii, Navitoclax, Research programme: Crohn's disease therapeutics, AK 101, IBD Program, MAK 11049, GI restricted TGF-β inhibitor, Research programme: mannose receptor-targeted therapeutic agents, Research programme: haematopoietic stem cell based ex vivo gene therapy, Xcimzane, TP317, TEM1657, SYGN 313, SYNB 8802, MORF 057, IBD Program, CU06, MSC1 & MSC2, Phospholipid A2 (PLA2), CKD-506, Implantable cell therapies, Neuregulin-4 (NRG-4), ABBV-154, AIB-301, ATI-2138 ITK/TXK/JAK3 Inhibitor, JAK1/JAK3 Inhibitor, ITK/TXK/JAK3 Inhibitor, ATH-105, ATH-63, DNL975, CrohnArt, and others are under different phases of Crohn's disease clinical trials.
- In February 2023, Janssen collaborated with Eli Lilly to address the lack of pediatric therapies for Crohn’s Disease. The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources to accelerate the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
- In February 2023, Agomab Therapeutics reported positive data from its Phase I study of AGMB-129 to treat Fibrostenosing Crohn’s Disease (FSCD). The trial was designed for assessing the tolerability, pharmacokinetics (PK), and safety of the oral, gastrointestinal (GI)-restricted, small molecule kinase ALK5 (TGFbRI or ALK5) inhibitor AGMB-129 in healthy participants. TGFb is a known master fibrosis regulator.
- In December 2022, Prometheus Biosciences reported results from its APOLLO-CD Phase IIa study of PRA023, demonstrating strong efficacy and favorable safety results. Based on the totality of the data in the study, Prometheus intends to advance PRA023 into Phase III studies for Crohn’s disease (CD) in 2023.
- In October 2022, Verily, and the Crohn’s & Colitis Foundation, announced an expanded strategic partnership. The collaboration will focus on building a longitudinal registry to accelerate research in Crohn’s disease and in ulcerative colitis, collectively known as inflammatory bowel disease (IBD).
- In April 2022, Engitix, entered into an agreement with Takeda to expand an existing collaboration and included the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. Under the terms of this agreement, Engitix and Takeda will collaborate in the confirmation and validation of targets and the preclinical development of therapeutics in IBD using Engitix’s unique extracellular matrix (ECM) discovery platform.
Request a sample and discover the recent advances in Crohn's disease treatment drugs @ Crohn's Disease Pipeline Report
The Crohn's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Crohn's disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Crohn's disease clinical trial landscape.
Crohn's Disease Overview
Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract in which inflammation extends from the mucosa to the serosa of the intestinal wall. It is a relapsing disease with remissions. Crohn's disease may affect only a small portion of the gastrointestinal tract at first, but it has the potential to spread widely. The digestive tract inflammation is followed by abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Crohn's disease can be painful and debilitating in people, sometimes leading to life-threatening complications. The inflammation caused by the intestine can be avoided between the patches of the diseased intestines. The signs and Crohn's disease symptoms observed in patients vary and can change over time.
A complete assessment based on clinical history, physical examination, and complementary diagnostic tests, such as assays for serological and fecal biomarkers, cross-sectional and endoscopic imaging, and histological evaluation of biopsy specimens, is required for the diagnosis of Crohn's disease. No single test can confirm a Crohn's disease diagnosis, and Crohn's disease symptoms are frequently confused with those of other conditions, such as bacterial infection.
The current Crohn's disease treatment stratifies the therapeutic agents based on the severity of the disease, with the ultimate goal of maintaining clinical remission. In patients, the treatment strategy frequently begins with a less effective, potentially less toxic treatment strategy, such as aminosalicylates (sulfasalazine), antibiotics, or corticosteroids (budesonide), with escalation to the highly effective but potentially more toxic treatment strategies, such as prednisone, immunomodulators (azathioprine, mercaptopurine, methotrexate), and biological therapy (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab, ustekinumab), in patients who failed each line of therapy.
Find out more about Crohn's disease treatment drugs @ Drugs for Crohn's Disease Treatment
A snapshot of the Crohn's Disease Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Guselkumab | Janssen | Phase III | Interleukin-23 subunit p19 inhibitors | Subcutaneous |
| RHB-104 | RedHill Biopharma | Phase III | Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors | Oral |
| Filgotinib | Galapagos/Gilead Sciences | Phase III | Janus kinase 1 inhibitors | Oral |
| Mirikizumab | Eli Lilly and Company | Phase III | Interleukin-23 subunit p19 inhibitors | Intravenous/ Subcutaneous |
| Ozanimod | Celgene Corporation | Phase III | Sphingosine 1 phosphate receptor modulators | Oral |
| Brazikumab | AstraZeneca | Phase III | Interleukin-23 subunit p19 inhibitors | Subcutaneous |
| Etrolizumab | Roche | Phase III | Alpha4beta7 integrin antagonist | Subcutaneous |
Learn more about the emerging Crohn's disease pipeline therapies @ Crohn's Disease Clinical Trials
Crohn's Disease Therapeutics Assessment
The Crohn's disease pipeline report proffers an integral view of the Crohn's disease emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Crohn's Disease Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Interleukin-23 subunit p19 inhibitors, Adenosine triphosphatase inhibitors, P-glycoprotein inhibitors, Phospholipase A2 inhibitors, Protein 50S ribosomal subunit inhibitors, Janus kinase 1 inhibitors, Sphingosine 1 phosphate receptor modulators, DNA-directed RNA polymerase inhibitors, Transcription factor inhibitors
- Key Crohn's Disease Companies: Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Celularity, Cerecor, GlaxoSmithKline, KangStem Biotech, Immunic, Alpha Cancer Technologies, Koutif Therapeutics, Tract Therapeutics, Trio medicines, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, JHL Biotech, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, AbbVie, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Engitix, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Assembly Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo, and others
- Key Crohn's Disease Pipeline Therapies: Guselkumab, ABP-654, RHB-104, Etrolizumab, PRA-023, AGMB-129, Filgotinib, Mirikizumab, Ozanimod, Brazikumab, Remestemcel-L, Rifaximin, Foralumab, ABX-464, Etrasimod, CYTO-201, Masitinib, HAV anti-MAP vaccine, Alequel, Cannabidiol, SHR0302, QBECO-SSI, PRV-6527, PF-06651600, MT-1303, TAK-018, SGX203, IMU 838, Alicaforsen, Bacteroides thetaiotaomicron, BT-11, JNJ-64304500, E6011, BMS-986165, Spesolimab, Aldesleukin, CBP-307, TD-1473, JKB-122, PDA-001, MDGN-002, GSK1070806, Furestem-CD, IMU-856, ACT-101, KT-1002, TregCel, TR8, CCX507, NP-178, NeuLara, JHL1255, Anti-inflammatory drug LIS, Brilacidin, Research programme: anti-fibrotic therapeutics Faecalibacterium Prausnitzii, Navitoclax, Research programme: Crohn's disease therapeutics, AK 101, IBD Program, MAK 11049, GI restricted TGF-β inhibitor, Research programme: mannose receptor-targeted therapeutic agents, Research programme: haematopoietic stem cell based ex vivo gene therapy, Xcimzane, TP317, TEM1657, SYGN 313, SYNB 8802, MORF 057, IBD Program, CU06, MSC1 & MSC2, Phospholipid A2 (PLA2), CKD-506, Implantable cell therapies, Neuregulin-4 (NRG-4), ABBV-154, AIB-301, ATI-2138 ITK/TXK/JAK3 Inhibitor, JAK1/JAK3 Inhibitor, ITK/TXK/JAK3 Inhibitor, ATH-105, ATH-63, DNL975, CrohnArt, and others
Dive deep into rich insights for new drugs for Crohn's disease treatment, visit @ Crohn's Disease Drugs
Table of Contents
| 1. | Crohn's Disease Pipeline Report Introduction |
| 2. | Crohn's Disease Pipeline Report Executive Summary |
| 3. | Crohn's Disease Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Crohn's Disease Clinical Trial Therapeutics |
| 6. | Crohn's Disease Pipeline: Late Stage Products (Pre-registration) |
| 7. | Crohn's Disease Pipeline: Late Stage Products (Phase III) |
| 8. | Crohn's Disease Pipeline: Mid Stage Products (Phase II) |
| 9. | Crohn's Disease Pipeline: Early Stage Products (Phase I) |
| 10. | Crohn's Disease Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Crohn's Disease Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Crohn's Disease Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Crohn's disease pipeline therapeutics, reach out @ Crohn's Disease Treatment Drugs
Related Reports
Crohn's Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Crohn's disease epidemiology trends.
Crohn's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn's disease companies, including Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Amgen, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., among others.
Irritable Bowel Syndrome Market
Irritable Bowel Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key irritable bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, among others.
Irritable Bowel Syndrome Pipeline
Irritable Bowel Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key irritable bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, among others.
Irritable Bowel Syndrome Epidemiology Forecast
Irritable Bowel Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the irritable bowel syndrome epidemiology trends.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
